InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,652.00
(
0.06%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,774.19
(
-0.03%
)
Post# of 251788
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: biotech_researcher post# 164145

Tuesday, 07/16/2013 6:26:21 PM

Tuesday, July 16, 2013 6:26:21 PM

Post# of 251788
According to the Credit Suisse report, "Gleevec/Glivec is used much more frequently in the first line setting in the EU than the US (74% vs. 46%)." Using those percentages, until the EPIC results are in, Iclusig only has the possibility of being used in second-line 26% of the time in the EU (other than T315I).
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up